Back

Finerenone-related initial declines in eGFR and urinary biomarkers of tubular injury: mechanistic insights from the FIVE-STAR trial

30 August 2026 (12:36 - 12:48)
Organised by: Logo
Congress Presentation Part of: Optimising pharmacotherapy in heart failure Aldosterone Antagonists ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Muthiah Vaduganathan

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

4 More presentations in this session

Presentation thumbnail
Evaluation of machine learning framework for personalized prediction of benefit from beta-blockers in myocardial infarction with preserved or mildly reduced ejection fraction
Doctor Y. Chen (Beijing, CN)
Abstract
Presentation thumbnail
The LUNAR-HF Trial: a randomised comparison of inclisiran versus evolocumab in ischaemic heart failure with reduced ejection fraction
Doctor R. Rascon Sabido (Veracruz, MX)
Abstract
Presentation thumbnail
Simultaneous versus sequential initiation of CKM therapies: an indirect comparison of CONFIDENCE and FIDELITY
Doctor J. Ostrominski (Boston, US)
Abstract
Presentation thumbnail
Finerenone and serum sodium in patients with heart failure and mildly reduced or preserved ejection fraction: an analysis of FINEARTS-HF
Doctor R. Ono (Glasgow, GB)
Abstract

Access the full session

Session thumbnail
Optimising pharmacotherapy in heart failure

The Event

Event poster

ESC Congress 2026

30 August 2026 12:36 CET
You may be interested in
thumbnail
Congress Presentation
Finerenone in patients with heart failure and deterioration in eGFR to <25ml/min/1.73m2 in the FINEARTS-HF Trial
17 May 2025
thumbnail
Congress Presentation
Impact of pulsed field ablation on urinary tubular markers in patients with atrial fibrillation: a comparison with radiofrequency ablation
12 April 2026
thumbnail
Congress Presentation
Multi-marker biomarker panel, adverse cardiovascular and kidney outcomes, and response to canagliflozin in the CANVAS Program
29 June 2021
thumbnail
Congress Presentation
Finerenone on arterial stiffness and cardiorenal biomarkers in patients with type 2 diabetes and chronic kidney disease: a randomized placebo-controlled mechanistic trial (FIVE-STAR)
18 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources